全文获取类型
收费全文 | 121918篇 |
免费 | 9385篇 |
国内免费 | 3185篇 |
专业分类
耳鼻咽喉 | 1063篇 |
儿科学 | 3125篇 |
妇产科学 | 1087篇 |
基础医学 | 8781篇 |
口腔科学 | 1362篇 |
临床医学 | 15268篇 |
内科学 | 29292篇 |
皮肤病学 | 777篇 |
神经病学 | 3466篇 |
特种医学 | 2631篇 |
外国民族医学 | 10篇 |
外科学 | 18121篇 |
综合类 | 19266篇 |
现状与发展 | 7篇 |
一般理论 | 2篇 |
预防医学 | 7872篇 |
眼科学 | 383篇 |
药学 | 11474篇 |
93篇 | |
中国医学 | 6887篇 |
肿瘤学 | 3521篇 |
出版年
2024年 | 156篇 |
2023年 | 2207篇 |
2022年 | 3166篇 |
2021年 | 5093篇 |
2020年 | 4664篇 |
2019年 | 4200篇 |
2018年 | 4198篇 |
2017年 | 3861篇 |
2016年 | 4574篇 |
2015年 | 5008篇 |
2014年 | 9301篇 |
2013年 | 9618篇 |
2012年 | 7408篇 |
2011年 | 7979篇 |
2010年 | 6542篇 |
2009年 | 6128篇 |
2008年 | 5722篇 |
2007年 | 5586篇 |
2006年 | 4925篇 |
2005年 | 4442篇 |
2004年 | 3968篇 |
2003年 | 2993篇 |
2002年 | 2485篇 |
2001年 | 2258篇 |
2000年 | 1721篇 |
1999年 | 1534篇 |
1998年 | 1342篇 |
1997年 | 1340篇 |
1996年 | 1302篇 |
1995年 | 1162篇 |
1994年 | 1262篇 |
1993年 | 937篇 |
1992年 | 892篇 |
1991年 | 812篇 |
1990年 | 789篇 |
1989年 | 669篇 |
1988年 | 621篇 |
1987年 | 434篇 |
1986年 | 409篇 |
1985年 | 464篇 |
1984年 | 408篇 |
1983年 | 255篇 |
1982年 | 312篇 |
1981年 | 258篇 |
1980年 | 226篇 |
1979年 | 179篇 |
1978年 | 162篇 |
1977年 | 133篇 |
1976年 | 117篇 |
1975年 | 74篇 |
排序方式: 共有10000条查询结果,搜索用时 750 毫秒
91.
92.
《Cancer cell》2021,39(11):1497-1518.e11
93.
目的 探讨高压氧(hyperbaric oxygen,HBO)治疗对慢性脑缺血(chronic cerebral ischemia,CCI)大鼠
学习记忆能力的影响及其作用机制。
方法 选取240只雄性SD大鼠随机分为假手术组、CCI组和HBO组,每组80只。采用双侧颈总动脉阻
断法建立CCI模型,HBO组建模12 h后开始进行HBO治疗28 d,压力0.2 MPa,每日1次,每次60 mi n。采用
Morri s水迷宫实验评估7、14、21、28 d大鼠的学习记忆能力,每个时间点20只,检测前均进行3 d训练,
记录各组大鼠的逃避潜伏时间、穿越平台次数。28 d后处死大鼠取海马组织进行HE染色评估神经元
损伤病理变化,RT-PCR法检测Nogo-A mRNA,Western blot法检测Nogo-A蛋白的表达水平。
结果 ①与假手术组比较,CCI 组7、14、21、28 d逃避潜伏时间均延长(均P<0.05),28 d跨越平台次
数减少(P<0.05);与CCI 组比较,HBO组7、14、21、28 d逃避潜伏时间均缩短(均P<0.05),28 d跨越
平台次数增加(P<0.05)。②HE染色显示HBO组神经元损伤程度较CCI组减轻;③CCI组Nogo-A mRNA
和Nogo-A蛋白表达水平均较假手术组升高(均P<0.05),HBO组表达水平均较CCI组下降(P<0.05)。
结论 HBO治疗可改善慢性脑缺血大鼠认知功能,其机制可能与下调海马组织中Nogo-A的表达水平
有关。 相似文献
94.
AbstractBackground: Approximately, 30–40% of patients experienced hearing loss under regular hemodialysis.Objective: This study reviewed our experience on treating acute hearing loss in patients under regular hemodialysis over the past two decades.Methods: Twenty-six patients having acute hearing loss under hemodialysis were divided into two groups based on their etiologies. Sixteen patients (16 ears) with sudden sensorineural hearing loss (SSHL) were assigned to Group A and 10 patients (13 ears) with endolymphatic hydrops (EH) were assigned to Group B.Results: No significant difference was noted between Groups A and B, regardless of hemodialysis duration, clinical manifestation, underlying systemic diseases, blood examination, and vestibular test battery. In contrast, serum osmolality was significantly lower in Group B (292?±?11 mOsm/kg) than in Group A (310?±?11 mOsm/kg). Furthermore, Group B (40?±?14?dB) had better mean hearing level than Group A (87?±?21?dB) in the initial audiogram, and a higher hearing improvement rate (69%) than Group A (19%).Conclusions and significance: Both SSHL and EH are major causes for precipitating acute hearing loss in hemodialysis patients. Compared to SSHL, the less deteriorated MHL and lower serum osmolality in EH provide two clues for differentiating acute hearing loss in hemodialysis patients. 相似文献
95.
Antoine Lin Hlne Sudour‐Bonnange Virginie Languillat‐Fouquet Herv Brisse Sabine Irtan Arnauld Verschuur Sabine Sarnacki Estelle Thbaud Aurore Coulomb‐L'Hermine Anne Notz‐Carrre Jean Michon Marie‐Dominique Tabone Ccile Boulanger Isabelle Pellier Claire Freycon Georges Audry Frdrique Dijoud Magali Morelle Christophe Bergeron Claudia Pasqualini 《Pediatric blood & cancer》2020,67(6)
96.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
97.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
98.
99.
100.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217